Investigator Initiated Trail: Lung or Gastrointestinal Cancers
Lilly Oncology is dedicated to delivering innovative treatment approaches with the goal of improving the outcomes of people living with cancer. We are driven to accelerate the pace and progress of cancer care by developing a broad portfolio of therapies, including those tailored to unique patients and those that modulate the immune system. Lilly’s commitment to improving the length and quality of people’s lives is achieved through its internal drug development programs and its support of Investigator Initiated Research.
Sintilimab is only available for use in studies based in China
Clinical in Scope
- Sintilimab alone or combined with other treatment for advanced disease, locally advanced disease or early stage disease
- Studies focused on lung cancer and gastrointestinal cancers
- Subtypes not well represented in past or current trials
- Precision medicine focused on enrichment studies to determine predictive biomarkers of response and potential resistance mechanism
- Real world study
- Proposals focusing on biomarker exploration, efficacy or resistance mechanism of Sintilimab alone, or combined with other agents in lung cancer and gastrointestinal cancers
Clinical Out of Scope
- Trials competing with the medically approved Sintilimab clinical development plan
- Concepts that compete against ongoing Lilly-sponsored trials or future development plans
Non-Clinical In Scope
- Proposals focusing on biomarker exploration, efficacy or resistance mechanism of Sintilimab alone, or combined with other agents in lung cancer and gastrointestinal cancers
Sintilimab is co-developed by Lilly & Innovent. Lilly & Innovent may separately or jointly provide support for Sintilimab IITs, including drug(s) and/or financial support
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.